The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Micro RNA s play a central role in molecular dysfunctions linking inflammation with cancer
Abstract
Summary: It is now largely admitted that a pro‐inflammatory environment may curtail anti‐tumor immunity and favor cancer initiation and progression. The discovery that small non‐coding regulatory RNA s, namely micro RNA s (mi RNA s), regulate all aspects of cell proliferation, differentiation, and function has shed a new light on regulatory mechanisms linking inflammation and cancer. Thus, mi RNA s such as miR‐21, miR‐125b, miR‐155, miR‐196, and miR‐210 that are critical for the immune response or hypoxia are often overexpressed in cancers and leukemias. Given the high number of their target transcripts, their deregulation may have a number of deleterious consequences, depending on the cellular context. In this review, we focus on how the factors encoded by transcripts targeted by these five mi RNA s, be they transcription factors, tumor‐suppressors, or regulators of different signaling pathways, can deregulate the immune response and favor pro‐tumor immunity. Furthermore, we expose how the misdirected action of the main regulators of these mi RNA s, such as nuclear factor κB (NF‐κB), activator protein‐1 (AP‐1), and signal transduction and activators of transcription (STAT) transcription factors, or AKT and transforming growth factor β (TGF β) signaling pathways, can contribute to decrease anti‐tumor immunity and enhance cell proliferation and oncogenesis. We conclude by briefly discussing about how these discoveries may possibly lead to the development of new mi RNA‐based cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773
Asangani, I. A., Rasheed, S. A. K., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., & Allgayer, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210856 · Cited by 1,882
MicroRNA-155 is induced during the macrophage inflammatory response
O'Connell, R. M., Taganov, K. D., Boldin, M. P., Cheng, G., & Baltimore, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610731104 · Cited by 1,866
Requirement of bic/microRNA-155 for Normal Immune Function
Rodriguez, A., Vigorito, E., Clare, S., Warren, M. V., Couttet, P., Soond, D. R., van Dongen, S., Grocock, R. J., Das, P. P., Miska, E. A., et al. (2007) · Science · doi:10.1126/science.1139253 · Cited by 1,833 · cited 4×
“El-miR-155 transgenic splenocytes produce more TNF upon LPS challenge than wildtype counterparts (27), while the expression of TNF transcript is down in miR-155 / mice (25, 26).”
BackgroundInfluentialMicroRNAs in Stress Signaling and Human Disease
Mendell, J. T., & Olson, E. N. (2012) · Cell · doi:10.1016/j.cell.2012.02.005 · Cited by 1,673
Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374
Tili, E., Michaille, J.-J., Cimino, A., Costinean, S., Dumitru, C. D., Adair, B., Fabbri, M., Alder, H., Liu, C. G., Calin, G. A., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5082 · Cited by 1,304 · cited 23×
“Qi J, Qiao Y, Wang P, Li S, Zhao W, Gao C. microRNA-210 negatively regulates LPS-induced production of pro-inflammatory cytokines by targeting NF-jB1 in murine macrophages.”
BackgroundInfluentialSelf-citationOncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma
Medina, P. P., Nolde, M., & Slack, F. J. (2010) · Nature · doi:10.1038/nature09284 · Cited by 1,073
A MicroRNA Signature of Hypoxia
Kulshreshtha, R., Ferracin, M., Wojcik, S. E., Garzon, R., Alder, H., Agosto-Perez, F. J., Davuluri, R., Liu, C.-G., Croce, C. M., Negrini, M., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01395-06 · Cited by 1,055
Self-citation
Cited by
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
miRNA Deregulation in Cancer Cells and the Tumor Microenvironment
Rupaimoole, R., Calin, G. A., Lopez-Berestein, G., & Sood, A. K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0893 · Cited by 689
microRNA Therapeutics in Cancer — An Emerging Concept
Shah, M. Y., Ferrajoli, A., Sood, A. K., Lopez-Berestein, G., & Calin, G. A. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.09.017 · Cited by 453
Hulsmans, M., & Holvoet, P. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt161 · Cited by 308
Wang, L., Zhang, H., Rodriguez, S., Cao, L., Parish, J., Mumaw, C., Zollman, A., Kamoka, M. M., Mu, J., Chen, D. Z., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.04.021 · Cited by 186
van Scheppingen, J., Iyer, A. M., Prabowo, A. S., Mühlebner, A., Anink, J. J., Scholl, T., Feucht, M., Jansen, F. E., Spliet, W. G., Krsek, P., et al. (2016) · Glia · doi:10.1002/glia.22983 · Cited by 60
The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer
Johansen, J. S., Calatayud, D., Albieri, V., Schultz, N. A., Dehlendorff, C., Werner, J., Jensen, B. V., Pfeiffer, P., Bojesen, S. E., Giese, N., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30291 · Cited by 47
Metadata
- Authors
- Tili, E., Michaille, J., & Croce, C. M.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2013-04-02
- Volume
- 253
- Issue
- 1
- Pages
- 167-184
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2065481320
- Cited by
- 206
- References
- 31
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.